WO2007099552A2 - Novel crystalline form of atovastatin hemi-magnesium - Google Patents
Novel crystalline form of atovastatin hemi-magnesium Download PDFInfo
- Publication number
- WO2007099552A2 WO2007099552A2 PCT/IN2007/000063 IN2007000063W WO2007099552A2 WO 2007099552 A2 WO2007099552 A2 WO 2007099552A2 IN 2007000063 W IN2007000063 W IN 2007000063W WO 2007099552 A2 WO2007099552 A2 WO 2007099552A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- atorvastatin hemi
- hemi
- water
- isopropanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Definitions
- the present invention relates to a novel crystalline form, solvate and the process for preparation of Atorvastatin hemi-magnesium.
- Atorvastatin hemi-magnesium is known by the chemical name ⁇ [R-(R* ,R*)]-2-(4- Fluorophenyl)- ⁇ , ⁇ -dihydroxy-5 -( 1 -methyl ethyl)-3 -phenyl-4- [(phenylamino)carbonyl] - 1 H- pyrrole-1-heptanoicacid ⁇ magnesium salt (2:1).
- Atorvastatin has the following formula.
- Atorvastatin as its hemi-calcium trihydrate, ⁇ [R-(R*,R*)]-2-(4-Fluorophenyl)- ⁇ , ⁇ - dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-l-heptanoic acid ⁇ calcium salt trihydrate has been marketed as Lipitor, used for the inhibition of biosynthesis of cholesterol.
- U.S. Pat No. 4,681,893 first disclosed and claimed Atorvastatin.
- U.S. Pat. No. 5,273,995 disclosed Atorvastatin hemi calcium salt and it also disclosed the process for preparation of Atorvastatin hemi calcium salt by hydrolysis of lactone with sodium hydroxide in aq.methanol and treatment with aqueous calcium chloride.
- U.S. Pat. No. 4,681,893 further discloses the pharmaceutically acceptable metal or amine salts of ring-opened hydroxy acids, process for preparation and their pharmaceutical compositions, method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions.
- the disclosed pharmaceutically acceptable metal salts contemplate the salts formed with sodium, potassium, calcium, magnesium, aluminum, iron and zinc ions.
- U.S. Pat. No 5,273,995 discloses pharmaceutically acceptable salts of [R-(R*, R*)] -2-(4- fluoro ⁇ henyl)- ⁇ , ⁇ -dihydroxy-5-((l-methylethyl)-3- ⁇ henyl-4-[( ⁇ henylamino)carbonyl]-lH- pyrrole- 1 -heptanoic acid, (2R-trans)-5-(4-fluorophenyl)-2-( 1 -methylethyl)-N,4-diphenyl- 1 - [2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethy 1] - 1 H-pyrrole-3 -carboxamide (the lactone form of the heptanoic acid), pharmaceutical composition and the process for preparation thereof.
- the disclosed pharmaceutically acceptable salts are derived by dissolving free acid or the lactone; preferably the lactone in aqueous or aqueous alcohol solvent or other suitable solvents with an appriopriate base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, l-deoxy-2(methylamino)-D-glucitol, magnesium hydroxide, zinc hydroxide, aluminum hydroxide or organic amines such as N-methylglucamine, choline, arginine and the like.
- an appriopriate base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, l-deoxy-2(methylamino)-D-glucitol, magnesium hydroxide, zinc hydroxide, aluminum hydroxide or organic amines such as N-methylglucamine, choline, arginine and the like.
- U.S. Pat. No. 5,273,995 discloses the process for preparation of calcium salt, N- methylglucamine salts of free acid.
- '995 patent also discloses that salts like potassium salt, hemi-magnesium salt, hemi-zinc salt or the l-deoxy-2(methylamino)-D-glucitol complex can be prepared analogously.
- the disclosed process for preparation of hemi-calcium salt involves the hydrolysis of lactone with sodium hydroxide in aqueous methanol and the resulted free acid is converted to its hemi-calcium salt by the slow addition of aqueous calcium chloride.
- the crystallinity of the salts prepared has not been disclosed.
- the prior art disclosed the process starting from the lactone. Thus there is a need of the industry for a process to prepare Atorvastatin hemi-magnesium salt without the isolation of lactone and carboxylic acid.
- Form A a crystalline polymorphic form of Atorvastatin hemi- magnesium salt
- Atorvastatin hemi-magnesium form A exhibits the X-ray powder diffraction pattern as depicted in Figure I, and the differential scanning calorimetry profile as depicted in Figure II.
- Fig I is the XRD pattern of Atorvastatin hemi-magnesium Form A
- Fig II is the DSC thermogram of Atorvastatin hemi-magnesium Form A
- Fig III is the XRD pattern of Atorvastatin hemi-magnesium isopropanol solvate
- Fig IV is the DSC thermogram of Atorvastatin hemi-magnesium isopropanol solvate
- Atorvastatin hemi-magnesium is prepared by treating (4R-Cis)-6-[2-(3-phenyl-4-( ⁇ henyl-carbomoyl)-(4-fluoro-phenyl)-5-(l -methyl ethyl)-pyrrol-l-yl)-ethyl]-2,2-dimethyl][l,3]dioxane-4-yl)-acetic acid tert.butyl ester in methanol with Hydrochloric acid preferably IN hydrochloric acid at temperature of 20 - 25 0 C for about 2 to 4 hrs.
- reaction mass pH is adjusted to slightly basic to neutral with hydrochloric acid.
- Reaction mass is concentrated by distillation of methanol and water preferably under vacuum at temperature below 45 0 C to about half to one-third of its original volume.
- the resulted mass is seeded with Atorvastatin hemi-magnesium at temperature of about 10 to 55 0 C, preferably at about 25 to 45 0 C and magnesium acetate preferably as aqueous solution is added at a temperature of about 10 to 55 0 C, preferably at about 25 to 45 0 C.
- Atorvastatin hemi-magnesium isopropanol solvate has the characteristic peaks at 2 theta values of 8.6, 11.5, 18.3, 18.9, 23.1, 28.1 ⁇ 0.2 in PXRD, contains about 15,000 to about 45,000 ppm of isopropanol.
- the crystalline Atorvastatin hemi-magnesium, isopropanol solvate is in the form of anhydrous or hydrate form containing water about 1.5 to about 6% w/w.
- Atorvastatin hemi-magnesium isopropanol solvate is converted to Atorvastatin hemi- magnesium form A by
- Atorvastatin hemi-magnesium form A obtained above exhibits the characteristic 2 theta values at 9.0, 10.0, 11.6, 18.3, 21.5, 27.9 ⁇ 0.2 deg in powdered XRD pattern.
- Crystalline Atorvastatin hemi-magnesium form A can also be prepared by - Dissolving Atorvastatin hemi-magnesium in a mixture of water and water miscible solvent selected from the group methanol, ethanol, isopropanol, n-propanol and acetone at about 3O 0 C to reflux temperature of solvent
- the crystalline polymorphic form of Atorvastatin hemi-magnesium has the characteristic 2 theta values at 9.0, 10.0, 11.6, 18.3, 21.5 (br), 27.9 (br) ⁇ 0.2 deg in powdered X-ray diffraction pattern.
- Step-I Preparation of amorphous Atorvastatin hemi-magnesium (4R-Cis)-6-[2-(3-phenyl-4-(phenyl-carbomoyl)-(4-fluoro-phenyl)-5-(l-methylethyl)- pyrrol-l-yl)-ethyl]-2,2-dimethyl][l,3]dioxane-4-yl)-acetic acid tert.butyl ester (120 gm) is suspended in methanol (2520 ml) and stirred for 10 min. at about 35 0 C.
- reaction mass is cooled to 20 - 25 0 C and IN Hydrochloric acid (240 ml) is added over 45 min.
- the reaction mass is maintained for 3 hrs at 20 - 25 0 C and 10% sodium hydroxide solution ( 252 ml) is added and maintained for 3 hrs at 20 - 25 0 C.
- pH of the reaction mass is adjusted to 7.6 with 6N hydrochloric acid (20 ml).
- Reaction mass is treated with activated carbon (3.7 gm) and filtered. The clear filtrate is concentrated to about l/3rd of its original volume below 45 0 C under vacuum and aqueous magnesium acetate solution (21.6 gm in 95 ml water) is added at temperature of 25 - 3O 0 C over 20 min.
- Step-2 Preparation of Atorvastatin hemi magnesium isopropanol solvate
- Isopropanol content is 41,000 ppm, water content is 3.10% w/w
- Step-3 Preparation of Crystalline Atorvastatin hemi-magnesium (from Isopropanol solvate)
- Atorvastatin hemi-magnesium isopropanol solvate 60 gm is suspended in water (480 ml).the resultant suspension is maintained for 30 min at 25 - 3O 0 C and filtered. The filtered product is washed with water (100 ml)) and dried at 50 - 55 0 C under vacuum to get crystalline Atorvastatin hemi-magnesium form A. Yield: 54.0 gm
- Atorvastatin hemi-magnesium (20 gm) is suspended in a mixture of ethanol (100 ml), water (100 ml); temperature of reaction mass is raised and maintained at 50 - 55 0 C for 30 min. The reaction mass is filtered and to the clear filtrate water (40 ml) is added and cooled the solution slowly to 20 - 25 0 C over a period of 1 hr. Reaction mass is maintained for lhr, further cooled and maintained at temperature of 0 - 5 0 C for 2 hrs.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a novel crystalline form of Atorvastatin hemi-magnesium and it further relates to a process for preparation of the same through the formation of Atorvastatin hemi-magnesium isopropanol solvate.
Description
"Novel crystalline form of Atorvastatin hemi-magnesium"
Field of the Invention: The present invention relates to a novel crystalline form, solvate and the process for preparation of Atorvastatin hemi-magnesium.
Background of the Invention: Atorvastatin hemi-magnesium is known by the chemical name { [R-(R* ,R*)]-2-(4- Fluorophenyl)-β ,δ-dihydroxy-5 -( 1 -methyl ethyl)-3 -phenyl-4- [(phenylamino)carbonyl] - 1 H- pyrrole-1-heptanoicacid} magnesium salt (2:1). Atorvastatin has the following formula.
Atorvastatin
Atorvastatin as its hemi-calcium trihydrate, {[R-(R*,R*)]-2-(4-Fluorophenyl)-β,δ- dihydroxy-5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-l-heptanoic acid} calcium salt trihydrate has been marketed as Lipitor, used for the inhibition of biosynthesis of cholesterol.
U.S. Pat No. 4,681,893 first disclosed and claimed Atorvastatin. U.S. Pat. No. 5,273,995 disclosed Atorvastatin hemi calcium salt and it also disclosed the process for preparation of Atorvastatin hemi calcium salt by hydrolysis of lactone with sodium hydroxide in aq.methanol and treatment with aqueous calcium chloride.
U.S. Pat. No. 4,681,893 further discloses the pharmaceutically acceptable metal or amine salts of ring-opened hydroxy acids, process for preparation and their pharmaceutical compositions, method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions. The disclosed pharmaceutically acceptable metal salts contemplate the salts formed with sodium, potassium, calcium, magnesium, aluminum, iron and zinc ions.
U.S. Pat. No 5,273,995 discloses pharmaceutically acceptable salts of [R-(R*, R*)] -2-(4- fluoroρhenyl)-β,δ-dihydroxy-5-((l-methylethyl)-3-ρhenyl-4-[(ρhenylamino)carbonyl]-lH- pyrrole- 1 -heptanoic acid, (2R-trans)-5-(4-fluorophenyl)-2-( 1 -methylethyl)-N,4-diphenyl- 1 - [2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethy 1] - 1 H-pyrrole-3 -carboxamide (the lactone form of the heptanoic acid), pharmaceutical composition and the process for preparation thereof.
The disclosed pharmaceutically acceptable salts are derived by dissolving free acid or the lactone; preferably the lactone in aqueous or aqueous alcohol solvent or other suitable solvents with an appriopriate base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, l-deoxy-2(methylamino)-D-glucitol, magnesium hydroxide, zinc hydroxide, aluminum hydroxide or organic amines such as N-methylglucamine, choline, arginine and the like.
U.S. Pat. No. 5,273,995 discloses the process for preparation of calcium salt, N- methylglucamine salts of free acid. '995 patent also discloses that salts like potassium salt, hemi-magnesium salt, hemi-zinc salt or the l-deoxy-2(methylamino)-D-glucitol complex can be prepared analogously. The disclosed process for preparation of hemi-calcium salt involves the hydrolysis of lactone with sodium hydroxide in aqueous methanol and the resulted free acid is converted to its hemi-calcium salt by the slow addition of aqueous calcium chloride. However the crystallinity of the salts prepared has not been disclosed.
The prior art disclosed the process starting from the lactone. Thus there is a need of the industry for a process to prepare Atorvastatin hemi-magnesium salt without the isolation of lactone and carboxylic acid.
Summary of the invention:
In one general aspect there is provided a process for the preparation of Atorvastain hemi- magnesium salt and the process steps include
a) hydrolysis of (4R-Cis)-6-[2-(3-phenyl-4-(phenyl-carbomoyl)-(4-fluoro-phenyl)-5-
( 1 -methylethyl)-pyrrol- 1 -yl)-ethyl]-2,2-dimethyl] [ 1 ,3]dioxane-4-yl)-acetic acid tertbutyl ester of formula I
Formula I b) treating with magnesium acetate gives the amorphous Atorvastatin hemi-magnesium salt
In another aspect of there is provided a crystalline polymorphic form of Atorvastatin hemi- magnesium salt (hereinafter designated as Form A)
Atorvastatin hemi-magnesium form A exhibits the X-ray powder diffraction pattern as depicted in Figure I, and the differential scanning calorimetry profile as depicted in Figure II.
In another aspect of there is provided a process for the preparation of Atorvastatin hemi- magnesium form A via the formation of Atorvastatin hemi-magnesium isopropanol solvate
Brief description of the drawings:
Fig I is the XRD pattern of Atorvastatin hemi-magnesium Form A
Fig II is the DSC thermogram of Atorvastatin hemi-magnesium Form A
Fig III is the XRD pattern of Atorvastatin hemi-magnesium isopropanol solvate
Fig IV is the DSC thermogram of Atorvastatin hemi-magnesium isopropanol solvate
Detailed description of the invention:
Thus in accordance with the present invention Atorvastatin hemi-magnesium is prepared by treating (4R-Cis)-6-[2-(3-phenyl-4-(ρhenyl-carbomoyl)-(4-fluoro-phenyl)-5-(l -methyl ethyl)-pyrrol-l-yl)-ethyl]-2,2-dimethyl][l,3]dioxane-4-yl)-acetic acid tert.butyl ester in methanol with Hydrochloric acid preferably IN hydrochloric acid at temperature of 20 - 250C for about 2 to 4 hrs. To the reaction mixture sodium hydroxide solution is added and maintained at temperature of 20-250C for about 2 to 6 hrs. Reaction mass pH is adjusted to slightly basic to neutral with hydrochloric acid. Reaction mass is concentrated by distillation of methanol and water preferably under vacuum at temperature below 450C to about half to one-third of its original volume. Optionally the resulted mass is seeded with Atorvastatin hemi-magnesium at temperature of about 10 to 550C, preferably at about 25 to 450C and magnesium acetate preferably as aqueous solution is added at a temperature of about 10 to 550C, preferably at about 25 to 450C. To the reaction mixture water is added and maintained for about 2 to 8 hrs at temperature of 10 to 550C preferably at 15 to 350C. The precipitated product is isolated and washed the wet cake with water and dried to get the amorphous form of Atorvastatin hemi-magnesium.
The above obtained amorphous Atorvastatin hemi-magnesium is dissolved in 3 to 12 volumes of methanol with reference to Atorvastatin hemi-magnesium at a temperature of 20 to 650C preferably at a temperature of about 20 to 400C. The obtained solution is filtered to remove the insolubles. To the clear filtrate water about 1 volume to 4 volumes is added at temperature of about 2O0C to 400C and maintained at about 2O0C to 4O0C for about 1 to 4 hrs. The reaction mass is concentrated to remove methanol under vacuum at temperature preferably below 450C. The concentrated mass is cooled and isopropanol about 3 to 8 volumes is added and maintained for about 1 to 8 hrs preferably for about 4 hrs. The reaction mass is optionally further diluted with about 1 to 4 volumes of isopropanol and the product is isolated. The wet cake is washed with isopropanol to get the Atorvastatin hemi-magnesium isopropanol solvate.
The above obtained Atorvastatin hemi-magnesium isopropanol solvate has the characteristic peaks at 2 theta values of 8.6, 11.5, 18.3, 18.9, 23.1, 28.1 ± 0.2 in PXRD, contains about 15,000 to about 45,000 ppm of isopropanol. The crystalline Atorvastatin hemi-magnesium, isopropanol solvate is in the form of anhydrous or hydrate form containing water about 1.5 to about 6% w/w.
Atorvastatin hemi-magnesium isopropanol solvate is converted to Atorvastatin hemi- magnesium form A by
• Suspending Atorvastatin hemi-magnesium isopropanol solvate in water
• Maintaining the suspension at room temperature
• Filtering the wet material and washing with water
• Drying the product below 550C to get Atorvastatin hemi-magnesium form A
Atorvastatin hemi-magnesium form A obtained above exhibits the characteristic 2 theta values at 9.0, 10.0, 11.6, 18.3, 21.5, 27.9 ± 0.2 deg in powdered XRD pattern.
Crystalline Atorvastatin hemi-magnesium form A can also be prepared by
- Dissolving Atorvastatin hemi-magnesium in a mixture of water and water miscible solvent selected from the group methanol, ethanol, isopropanol, n-propanol and acetone at about 3O0C to reflux temperature of solvent
- Treating the above solution with activated carbon - Cooling the mass to 100C - 300C
Adding water to the above obtained solution till turbidity appears
- Cooling the mass to about 100C to 2O0C and maintaining at the same temperature isolating the product and drying at temperature of 40 to 550C to get Atorvastatin hemi-magnesium form A
The crystalline polymorphic form of Atorvastatin hemi-magnesium has the characteristic 2 theta values at 9.0, 10.0, 11.6, 18.3, 21.5 (br), 27.9 (br) ± 0.2 deg in powdered X-ray diffraction pattern.
The required 4(4R-CIS)-6-[2-(3-phenyl-4-(phenyl-carbomoyl)-(4-fluoro-phenyl)-5-(l- methylethyl)-pyrrol-l-yl)-ethyl]-2,2-dimethyl][l,3]dioxane-4-yl)-acetic acid tert.butyl ester can be obtained commercially or can be prepared by reported prior art methods.
The invention is further illustrated with a few non-limiting examples
Example 1: Preparation of Crystalline Atorvastatin hemi-magnesium
Step-I: Preparation of amorphous Atorvastatin hemi-magnesium (4R-Cis)-6-[2-(3-phenyl-4-(phenyl-carbomoyl)-(4-fluoro-phenyl)-5-(l-methylethyl)- pyrrol-l-yl)-ethyl]-2,2-dimethyl][l,3]dioxane-4-yl)-acetic acid tert.butyl ester (120 gm) is suspended in methanol (2520 ml) and stirred for 10 min. at about 350C. The reaction mass is cooled to 20 - 250C and IN Hydrochloric acid (240 ml) is added over 45 min. The reaction mass is maintained for 3 hrs at 20 - 250C and 10% sodium hydroxide solution ( 252 ml) is added and maintained for 3 hrs at 20 - 250C. pH of the reaction mass is adjusted to 7.6 with 6N hydrochloric acid (20 ml). Reaction mass is treated with activated carbon (3.7 gm) and filtered. The clear filtrate is concentrated to about l/3rd of its original
volume below 450C under vacuum and aqueous magnesium acetate solution (21.6 gm in 95 ml water) is added at temperature of 25 - 3O0C over 20 min. To the reaction mass water (950 ml) is added over 10 min and maintained for 4 hrs at 25 - 3O0C. The precipitated product is filtered; wet cake is washed with water (100 ml) and dried at 40 - 450C under vacuum to get amorphous Atorvastatin hemi-magnesium. Yield: 83 gm. Water content: 5.86% w/w
Step-2: Preparation of Atorvastatin hemi magnesium isopropanol solvate
Water (115 ml) is added to a solution of Atorvastatin hemi-magnesium (82 gm) in methanol (328 ml) at temperature of 25 - 3O0C and maintained for 2 hrs. Solvent is distilled off under vacuum below 450C. Reaction mass is cooled, isopropanol (410 ml) is added and maintained at temperature of 25 - 3O0C for 4 hrs. To the reaction mass 2nd lot of isopropanol (164 ml) is added and maintained for 15 min. The precipitated product is filtered; wet cake is washed with isopropanol (120 ml) and dried at 50 - 550C under vacuum to get Atorvastatin hemi magnesium isopropanol solvate. Yield: 60 gm
Isopropanol content is 41,000 ppm, water content is 3.10% w/w
Step-3: Preparation of Crystalline Atorvastatin hemi-magnesium (from Isopropanol solvate)
Atorvastatin hemi-magnesium isopropanol solvate (60 gm) is suspended in water (480 ml).the resultant suspension is maintained for 30 min at 25 - 3O0C and filtered. The filtered product is washed with water (100 ml)) and dried at 50 - 550C under vacuum to get crystalline Atorvastatin hemi-magnesium form A. Yield: 54.0 gm
Water content is 4.48% w/w
Example 2: Preparation of Crystalline Atorvastatin hemi-magnesium
Atorvastatin hemi-magnesium (20 gm) is suspended in a mixture of ethanol (100 ml), water (100 ml); temperature of reaction mass is raised and maintained at 50 - 550C for 30 min. The reaction mass is filtered and to the clear filtrate water (40 ml) is added and cooled the solution slowly to 20 - 250C over a period of 1 hr. Reaction mass is maintained for lhr, further cooled and maintained at temperature of 0 - 50C for 2 hrs. Product is filtered; wet cake is washed with mixture of ethanol and water (4:6, 50 ml) and dried at temperature of 50 - 550C under vacuum to get crystalline Atorvastatin hemi-magnesium form A. Yield: 17 gm
Water content is 4.37% w/w
Claims
1. Crystalline form A of Atorvastatin hemi-magnesium
2. Crystalline form A of Atorvastatin hemi-magnesium of claim 1, further characterized by an X-ray powder diffraction pattern having peaks at about 9.0, 10.0, 11.6, 18.3, 21.5, 27.9 ± 0.2 degrees two-theta
3. Crystalline form A of Atorvastatin hemi-magnesium of claim 1, which exhibits characteristic X-ray powder diffraction pattern as depicted in Fig. 1
4. Crystalline form A of Atorvastatin hemi-magnesium of claim 1 , which exhibits DSC thermogram as depicted in Fig. 2
5. A process for the preparation of crystalline Atorvastatin hemi-magnesium comprises
- Treating (4R-Cis)-6-[2-(3-phenyl-4-(phenyl-carbomoyl)-(4-fluoro-phenyl)-5- ( 1 -methyl ethyl)-pyrrol- 1 -yl)-ethyl] -2,2-dimethyl] [1,3] dioxane-4-yl)-acetic acid tert.butyl ester with HCl followed by sodium hydroxide solution - Concentrating the reaction mass under vacuum at slightly basic or under neutral condition
Adding magnesium acetate at temperature of about 10 to 550C, Optionally adding water and maintaining the reaction mass for about 2 to 8 hrs at temperature of 10 to 550C preferably at 15 to 350C. - Isolating the precipitated Atorvastatin hemi-magnesium.
- Dissolving Atorvastatin hemi-magnesium in methanol at a temperature of about 20 to 650C.
- Filtering the mass and adding water at about 2O0C to 4O0C
- Concentrating the reaction mass. - Adding isopropanol and isolating the Atorvastatin hemi-magnesium isopropanol solvate - Treating the Atorvastatin hemi-magnesium isopropanol solvate with water
- Isolating and drying the product to get Atorvastatin hemi-magnesium form A
6. A process for the preparation of crystalline Atorvastatin hemi-magnesium form A comprises
- Dissolving Atorvastatin hemi-magnesium in a mixture of water and water miscible solvent selected from the group methanol, ethanol, isopropanol, n-propanol and acetone
- Diluting the mass with water - Isolating the product and drying to get Atorvastatin hemi-magnesium form A
7. Atorvastatin hemi-magnesium isopropanol solvate
8. Atorvastatin hemi-magnesium isopropanol solvate of claim 7, further characterized by an X-ray powder diffraction pattern having peaks at about 8.6, 11.5, 18.3, 18.9,
23.1, 28.1 ± 0.2 degrees two-theta
9. Atorvastatin hemi-magnesium isopropanol solvate of claim 7, which exhibits characteristic X-ray powder diffraction pattern as depicted in Fig. 3
10. Atorvastatin hemi-magnesium isopropanol solvate of claim 7, which exhibits DSC thermogram as depicted in Fig. 4
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN377CH2006 | 2006-03-02 | ||
IN377/CHE/2006 | 2006-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007099552A2 true WO2007099552A2 (en) | 2007-09-07 |
WO2007099552A3 WO2007099552A3 (en) | 2007-10-25 |
Family
ID=38459440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2007/000063 WO2007099552A2 (en) | 2006-03-02 | 2007-02-20 | Novel crystalline form of atovastatin hemi-magnesium |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007099552A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100850850B1 (en) | 2008-01-25 | 2008-08-06 | 주식회사종근당 | Method for the preparation of atorvastatin and intermediates used therein |
WO2009063476A1 (en) * | 2007-11-16 | 2009-05-22 | Biocon Limited | A crystalline form of atorvastatin hemi magnesium salt and a process thereof |
EP2130819A2 (en) | 2008-04-10 | 2009-12-09 | Ranbaxy Laboratories Limited | Crystalline forms of atorvastatin magnesium |
WO2009157005A1 (en) * | 2008-06-26 | 2009-12-30 | Biocon Limited | Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof |
EP2172452A1 (en) * | 2005-05-03 | 2010-04-07 | Ranbaxy Laboratories Limited | Preparation of crystalline atorvastatin magnesium |
US10252993B2 (en) | 2010-07-28 | 2019-04-09 | Kyongbo Pharm | Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same |
CN111362856A (en) * | 2020-04-29 | 2020-07-03 | 福建海西新药创制有限公司 | Method for producing atorvastatin calcium by using micro-reaction device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336405A1 (en) * | 2002-02-14 | 2003-08-20 | Ranbaxy Laboratories, Ltd. | Formulations of atorvastatin stabilized with alkali metal additions |
EP1577297A1 (en) * | 2004-03-17 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Process for the production of atorvastatin calcium in amorphous form |
WO2006117761A2 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Magnesium salts of hmg-coa reductase inhibitors |
-
2007
- 2007-02-20 WO PCT/IN2007/000063 patent/WO2007099552A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336405A1 (en) * | 2002-02-14 | 2003-08-20 | Ranbaxy Laboratories, Ltd. | Formulations of atorvastatin stabilized with alkali metal additions |
EP1577297A1 (en) * | 2004-03-17 | 2005-09-21 | Ranbaxy Laboratories, Ltd. | Process for the production of atorvastatin calcium in amorphous form |
WO2006117761A2 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Magnesium salts of hmg-coa reductase inhibitors |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172452A1 (en) * | 2005-05-03 | 2010-04-07 | Ranbaxy Laboratories Limited | Preparation of crystalline atorvastatin magnesium |
WO2009063476A1 (en) * | 2007-11-16 | 2009-05-22 | Biocon Limited | A crystalline form of atorvastatin hemi magnesium salt and a process thereof |
KR100850850B1 (en) | 2008-01-25 | 2008-08-06 | 주식회사종근당 | Method for the preparation of atorvastatin and intermediates used therein |
WO2009093776A1 (en) * | 2008-01-25 | 2009-07-30 | Chong Kun Dang Pharmaceutical Corp. | Method for the preparation of atorvastatin and intermediates used therein |
US8178697B2 (en) | 2008-01-25 | 2012-05-15 | Chong Kun Dang Pharmaceutical Corp. | Method for the preparation of atorvastatin and intermediates used therein |
EP2130819A2 (en) | 2008-04-10 | 2009-12-09 | Ranbaxy Laboratories Limited | Crystalline forms of atorvastatin magnesium |
EP2130819A3 (en) * | 2008-04-10 | 2009-12-23 | Ranbaxy Laboratories Limited | Crystalline forms of atorvastatin magnesium |
WO2009157005A1 (en) * | 2008-06-26 | 2009-12-30 | Biocon Limited | Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof |
US10252993B2 (en) | 2010-07-28 | 2019-04-09 | Kyongbo Pharm | Crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same |
CN111362856A (en) * | 2020-04-29 | 2020-07-03 | 福建海西新药创制有限公司 | Method for producing atorvastatin calcium by using micro-reaction device |
CN111362856B (en) * | 2020-04-29 | 2023-08-18 | 福建海西新药创制股份有限公司 | Method for producing atorvastatin calcium by utilizing micro-reaction device |
Also Published As
Publication number | Publication date |
---|---|
WO2007099552A3 (en) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI94339C (en) | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts | |
WO2007099552A2 (en) | Novel crystalline form of atovastatin hemi-magnesium | |
JP2009221216A (en) | Crystalline form of atorvastatin | |
CZ2004126A3 (en) | Crystalline forms VI and VII of atorvastatin calcium salt | |
JP2006503024A (en) | Type VI atorvastatin calcium or its hydrate | |
EP1732886B1 (en) | Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin | |
EP1853559A1 (en) | An improved process for the preparation of atorvastatin and intermediates | |
US8188300B2 (en) | Atorvastatin calcium propylene glycol solvates | |
US7615647B2 (en) | Process for producing atorvastatin hemicalcium | |
US20090240064A1 (en) | Crystalline form of atorvastatin hemi-calcium | |
US20090099371A1 (en) | Process for the preparation of amorphous atorvastatin calcium salt | |
CA2578722C (en) | Process for atorvastatin calcium amorphous | |
US7361772B2 (en) | Process for the production of atorvastatin calcium | |
WO2005073187A1 (en) | Improved process for the preparation of amorphous atorvastatin calcium | |
US20050165242A1 (en) | Process for the preparation of amorphous atorvastatin calcium | |
EP2373609A1 (en) | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates | |
WO2005033078A1 (en) | Process for the production of atorvastatin calcium | |
WO2006048888A1 (en) | Novel process for the preparation of amorphous atorvastatin calcium salt | |
EP2130819A2 (en) | Crystalline forms of atorvastatin magnesium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07736528 Country of ref document: EP Kind code of ref document: A2 |